Humanoid Robot Mass Adoption Will Start In 2028, Says Bank Of America
Neura Robotics shows off 4NE-1, a humanoid robot, in an outdoor ad campaign
Humanoid robots will begin a mass adoption trend for commercial use as early as 2028, according to a new Bank of America research report. Annual shipments could hit 1 million by 2030, with a production cost of just $17,000 per unit.
'BofA Global Research believes the adoption of humanoid robots will follow a three-stage development trajectory in the coming decade, starting from industrial and logistic applications, then on to business services, and finally to household use,' a company representative told me via email. 'In the long run, BofA Global Research expects the total units in ownership for humanoid robots to reach an estimated three billion units globally by 2060.'
That three billion unit projection is based on three assumptions:
According to the report, the first mass commercializations period for humanoid robots will be from 2028 to 2034, and it will focus on commercial use. The second mass adoption period will be for home and all other uses, and will run from 2035 onwards. Futurists like Peter Diamandis have speculated that robots will help us in our homes with laundry, vacuuming, dishes, and all other tasks, and serve multiple purposes in healthcare, elder care, manufacturing, transport, and the service industry.
The future is starting now: Bank of America says that humanoid robot manufactures will ship 18,000 units this year, in 2025. By 2030, researchers expect that shipments will reach up to 10 million units globally per year.
Projected humanoid robot shipments to 2060.
Interestingly, the report suggests that the vast majority of humanoid robots will be household tools, with about two billion of the three billion shipped by 2060 in use in private homes, versus about a billion in the service industry, and only a few hundred million in industrial settings.
If so, that could be good news for human workers: many of the household robots will be replacing unpaid work that people do for themselves, rather than paid work by employees.
There are still challenges to mass adoption, the Bank of America says:
In addition, there is regulatory risk: will nations regulate against humanoid robots in ways that delay or entirely stop deployments? Workers could rise up against them as well, with a historical precedent being the Luddite movement in the early 1800s in which textile workers protested against mechanized looms.
Over 100 global manufacturers are working on humanoid robots, and it's a tough challenge.
Humanoid robot components, with cost estimates for each part.
One of the biggest: dextrous hands. Almost 20% of the cost of a robot is in the hands alone. One of the reasons why: more than half the complexity of a humanoid robot body is in the hands, Sanctuary AI CEO Geordie Rose told me last year.
Other major cost components include rotary actuators in joints, linear actuators, and the chips that drive the brain of a humanoid robot.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Over 200 Central Banks Reportedly Dump $48 Billion In US Treasuries Amid Concerns Over Dollar's Stability: 'The Drop Is Unusual'
Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. More than 200 Central banks and foreign entities have withdrawn a substantial amount of U.S. Treasuries from the New York Federal Reserve, signaling potential concerns over the stability of the U.S. dollar. What Happened: The New York Fed's custody holdings of U.S. Treasuries and other assets have seen a significant decline. The holdings dropped by $17 billion last week and have plummeted by $48 billion since late March, coinciding with the onset of the trade tensions sparked by President Donald Trump's tariffs, reported Fortune Trending: Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing — Bank of America's managing director and U.S. rates strategist, Meghan Swiber and fellow strategist, Katie Craig, expressed significant concern over the withdrawal of foreign private investors from the Treasury securities market. Swiber and Craig commented, 'This drop is unusual.' Typically, the cash generated from the sale of U.S. debt is placed in the New York Fed's reverse repurchase facility, where it is exchanged for Treasuries as collateral. However, that trend has recently reversed, with foreign participation in the facility declining by $15 billion since late March. This points to a notable reduction in U.S. assets held by foreigners at the Fed — roughly $63 billion in just over two months. Swider told Fortune, "We're of the view that deficits are going to continue to climb higher in the coming years, and what we struggle with is, 'Who is going to help support that higher level of supply?' As per Torsten Sløk, chief economist at Apollo Global Management, foreign buyers constitute about 30% of the U.S. Treasury market, and any decrease in their participation could compel the Treasury to offer higher yields to attract buyers, affecting interest rates across the economy, reported It Matters: The recent withdrawal of U.S. Treasuries by central banks and foreign entities adds to the growing concerns about the stability of the U.S. dollar and the potential impact on the global economy. This trend has been accompanied by a rise in Treasury yields, which could signal a weakening of foreign demand for U.S. debt, further exacerbating the situation. These developments are particularly noteworthy given the historical relationship between the U.S. dollar and Treasury yields. However, this pattern has seen a significant divergence since April 2025, potentially indicating a shift in global confidence in U.S. assets. As the U.S. dollar's status as the world's reserve currency and the confidence in the U.S. government's ability to meet its financial obligations are called into question, the U.S. may face increased borrowing costs, potentially impacting various sectors of the economy. On a year-to-date basis, iShares 20+ Year Treasury Bond ETF (NASDAQ:TLT) fell 1.05%, while iShares 7-10 Year Treasury Bond ETF (NASDAQ:IEF) climbed 2.21%. Read Next: Invest early in CancerVax's breakthrough tech aiming to disrupt a $231B market. Back a bold new approach to cancer treatment with high-growth potential. If there was a new fund backed by Jeff Bezos offering a 7-9% target yield with monthly dividends would you invest in it? Image via ShutterstockThis article Over 200 Central Banks Reportedly Dump $48 Billion In US Treasuries Amid Concerns Over Dollar's Stability: 'The Drop Is Unusual' originally appeared on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
4 hours ago
- Yahoo
Bank of America Stock (BAC) Nears Record High as Pivotal Earnings Report Looms
Bank of America (BAC) is scheduled to report its Q2 2025 earnings on July 16, with analysts forecasting $0.90 per share, reflecting modest 8% year-over-year growth. I believe BAC is well-positioned to beat expectations, supported by conservative loan loss provisioning, ongoing share buybacks, strength in its Global Markets division, and higher net interest income amid slower-than-expected Federal Reserve rate cuts. Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter BAC stock currently trades at $45, within striking distance of its all-time high of $47 per share. With resistance clearly set, BAC stock will need a strong catalyst to make further headway beyond $50 per share. Given the lack of clear catalysts, I remain Neutral on BAC stock. It currently trades at 1.66x tangible book value and 12.6x 2025 earnings—a valuation that's lower than peers like JPMorgan Chase (JPM), but still richer than that of many U.S. regional banks. Heading into Q2 2025, Bank of America's provisioning appears notably conservative. The bank's macroeconomic outlook assumes an unemployment rate of just below 5% by the end of 2025, remaining at that level through 2026, which is slightly more pessimistic than the Federal Reserve's projection of 4.5% for both years. Similarly, Bank of America forecasts 1% GDP growth in Q4 2025, undercutting the Fed's more optimistic estimate of 1.4%. In short, Bank of America's current reserves already reflect a cautious economic view, making it unlikely to build a significant provision in Q2 2025. The bank appears to have already accounted for a moderate economic slowdown later this year and into 2026. Analysts expect Bank of America to deliver earnings of $0.90/share in Q2 2025, up 8% year-over-year. This would represent a marked slowdown from the 18% annual increase observed in the first quarter of 2025. I believe the projected 8% EPS growth is overly conservative. Based on my estimates, share repurchases alone could contribute around 5% EPS growth. Additionally, Bank of America is likely to raise its net interest income (NII) guidance, as the Federal Reserve is now expected to deliver only two rate cuts in 2025, compared to the four cuts the bank had initially anticipated in its own outlook. I also expect slightly stronger performance from the Global Markets division, supported by heightened market volatility early in Q2 2025, which could contribute a paltry $0.02 per share to earnings. In summary, I expect Bank of America to modestly beat consensus earnings estimates, driven by conservative provisioning, upward NII revisions, and a slight lift from trading activity. My forecast is EPS of approximately $0.92 for Q2 2025. Based on my projections, Bank of America is on track to deliver earnings of approximately $3.57 per share in 2025, assuming consistent 8% growth in both Q3 and Q4 of 2024. This would translate to a return on tangible book value of around 13% for the year. However, this solid profitability appears to be largely priced in, with BAC stock trading at 1.66x its tangible book value of $27.12 per share. Its 2025 P/E multiple of 12.6x is more attractive than that of large peers like JPMorgan Chase (14.6x), but still above the average for regional banks, which trade closer to 10.7x forward earnings. Looking ahead to 2026, earnings growth is expected to moderate, with no repeat of the Global Markets tailwind and potential pressure from anticipated Fed rate cuts. Given this outlook, I believe a Hold rating is appropriate for BAC at current levels. This cautious stance is also supported by Berkshire Hathaway's ongoing reduction in its BAC stake, despite the stock remaining the firm's fourth-largest holding, which comprises 10.19% of Buffett's portfolio. The limited upside potential suggests it's wise to stay neutral for now. Turning to Wall Street, Bank of America earns a Strong Buy consensus rating based on 18 Buy and 2 Hold ratings over the past three months. Notably, not a single analyst is bearish on Bank of America. The average BAC stock price target is $49.38, implying a 9% potential upside. Bank of America's macroeconomic outlook remains more conservative than the Federal Reserve's, which suggests its earnings are better insulated in the event of a slowdown in U.S. economic activity later in 2025 and into 2026. I expect BAC to slightly beat Q2 2025 earnings estimates, supported by stronger net interest income, continued share repurchases, and a modest profitability boost from the Global Markets division. That said, I remain neutral on the stock. Like Warren Buffett, who has recently trimmed Berkshire's position in BAC, I believe the bank's solid profitability is already reflected in the stock's price, which trades at 1.66x tangible book value. Lastly, while Wall Street analysts maintain a Strong Buy rating, the implied upside of just 9.59% suggests limited near-term reward for new investors at current levels. Disclaimer & DisclosureReport an Issue Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
6 hours ago
- Business Wire
Verdiva Bio to Present New Data Highlighting Once-Weekly Potential of Its Investigational Oral Obesity Candidates at the ADA 85th Scientific Sessions
LONDON & SAN FRANCISCO--(BUSINESS WIRE)--Verdiva Bio Limited ('Verdiva' or 'the Company') a clinical-stage biopharmaceutical company focused on developing innovative therapies for obesity and cardiometabolic disorders, will present new data showcasing the once-weekly potential of Verdiva's investigational oral GLP-1RA and amylin analog peptide candidates at the American Diabetes Association (ADA) 85th Scientific Sessions. 'These presentations underscore the potential value of our compounds as the only once-weekly oral amylin and oral GLP-1 receptor agonist (RA) candidates known to be advancing into clinical studies," said Dr. Mohamed Eid, CMO, Verdiva Bio Share 'Our first data presentation as Verdiva Bio at the prestigious ADA meeting marks a key milestone for our team. These presentations underscore the potential value of our compounds as the only once-weekly oral amylin and oral GLP-1 receptor agonist (RA) candidates known to be advancing into clinical studies,' stated Dr. Mohamed Eid, CMO at Verdiva. 'The early clinical and preclinical data not only show the potential of these compounds individually, but also the additive effect they may have in combination, highlighting the flexibility of our modular portfolio approach. At Verdiva Bio, we are committed to developing convenient, patient-friendly and commercially scalable therapeutic options for obesity, cardiometabolic disorders and related complications. We're excited about the potential of our once-weekly oral peptide candidates to help address this global health challenge.' VRB-101: An investigational once-weekly oral GLP-1 analog This presentation highlights new clinical pharmacokinetic data for VRB-101, an investigational, once-weekly, cAMP-biased oral GLP-1RA formulated with Verdiva's clinically validated, proprietary oral delivery technology T2026. Phase 1 results demonstrated that oral VRB-101 achieved drug levels comparable to, or exceeding, those of currently available once-weekly injectable GLP-1RA therapies. These findings support continued investigation of VRB-101 as a potential once-weekly, scalable oral therapeutic option for both weight reduction and long-term weight maintenance, with the potential to exert potent weight reduction and may improve adherence via a more patient-friendly dosing regimen. Poster Presentation #069 Title: VRB-101 is a potent oral GLP-1 tablet with once-weekly dosing potential Date/Time: June 21, 2025, 12:30–1:30 p.m. Central Time Location: Poster Hall (Hall F1) 068, McCormick Place Convention Center VRB-103: Efficacy of novel once-weekly oral amylin analog as a monotherapy, and in combination with VRB-101 in vivo A second presentation will share novel preclinical data on VRB-103, an investigational potentially once-weekly oral amylin analog, tested alone and in combination with VRB-101. In preclinical models, the rationally designed peptide combination showed an additive effect on body weight reduction. Additionally, co-formulation of these peptides in a single tablet with T2026 maintained comparable plasma exposure for both compounds. These data support continued development of VRB-103 as both a monotherapy and in combination with VRB-101. Poster Presentation #068 Title: Efficacy of a novel oral amylin analog and the development of an oral GLP-1/amylin co-formulated tablet to produce high in vivo plasma exposures Date/Time: June 21, 2025, 12:30–1:30 p.m. Central Time Location: Poster Hall (Hall F1) 068, McCormick Place Convention Center About Verdiva Bio Verdiva Bio is committed to developing next-generation therapies to help people living with obesity, cardiometabolic disorders, and related complications achieve better outcomes via more patient-friendly therapeutic options. Verdiva's most advanced product candidate is VRB-101, an oral GLP-1 peptide in clinical development that has demonstrated potential efficacy in a phase 1 study in Australia, which also confirmed the viability of once-weekly dosing potential. The Company is also developing a portfolio of amylin molecules, including oral and subcutaneous agonists, and other undisclosed programs that offer the potential for enhanced efficacy and improved tolerability. The Verdiva team will harness the emerging science in gut-brain biology and leverage their history of successful drug development to advance novel therapeutic options aiming to transform the lives of millions living with obesity worldwide. For more information, please visit
